DPC 963
Alternative Names: DMP 963Latest Information Update: 16 Jan 2008
At a glance
- Originator Bristol-Myers Squibb
- Class Antiretrovirals; Small molecules
- Mechanism of Action RNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 16 Nov 2000 A preclinical study in cynomolgus monkeys has been added to the pharmacokinetics section
- 26 May 2000 A preclinical study has been added to the pharmaockinetics section
- 22 Mar 1999 A study of the activity of DPC 963 against resistant strains of HIV has been added to the antimicrobial activities section